HSP90AB1 and neoplasm: Reprogramming of tumor microenvironment. Beyond direct tumor cell effects, Hsp90 inhibitors target immunosuppressive cell populations (e.g., Tregs, MDSCs, TAMs, CAFs) and cytokines within the TME, shifting the balance toward antitumor immunity.